NO20004946L - Humanisert antistoff mot human vevsfaktor (TF) og fremgangsmåte ved fremstilling av det humaniserte antistoff - Google Patents

Humanisert antistoff mot human vevsfaktor (TF) og fremgangsmåte ved fremstilling av det humaniserte antistoff

Info

Publication number
NO20004946L
NO20004946L NO20004946A NO20004946A NO20004946L NO 20004946 L NO20004946 L NO 20004946L NO 20004946 A NO20004946 A NO 20004946A NO 20004946 A NO20004946 A NO 20004946A NO 20004946 L NO20004946 L NO 20004946L
Authority
NO
Norway
Prior art keywords
chain
humanized antibody
region
humanized
antibody
Prior art date
Application number
NO20004946A
Other languages
English (en)
Norwegian (no)
Other versions
NO20004946D0 (no
Inventor
Koh Sato
Hideki Adachi
Naohiro Yabuta
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of NO20004946D0 publication Critical patent/NO20004946D0/no
Publication of NO20004946L publication Critical patent/NO20004946L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20004946A 1998-04-03 2000-10-02 Humanisert antistoff mot human vevsfaktor (TF) og fremgangsmåte ved fremstilling av det humaniserte antistoff NO20004946L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9185098 1998-04-03
PCT/JP1999/001768 WO1999051743A1 (en) 1998-04-03 1999-04-02 Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody

Publications (2)

Publication Number Publication Date
NO20004946D0 NO20004946D0 (no) 2000-10-02
NO20004946L true NO20004946L (no) 2000-12-04

Family

ID=14038058

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004946A NO20004946L (no) 1998-04-03 2000-10-02 Humanisert antistoff mot human vevsfaktor (TF) og fremgangsmåte ved fremstilling av det humaniserte antistoff

Country Status (19)

Country Link
US (2) US6677436B1 (da)
EP (2) EP1069185B1 (da)
JP (2) JP3998419B2 (da)
KR (1) KR20010042435A (da)
CN (1) CN1303431A (da)
AT (1) ATE512225T1 (da)
AU (1) AU752730B2 (da)
BR (1) BR9909382A (da)
CA (1) CA2325346A1 (da)
DK (1) DK1069185T3 (da)
ES (1) ES2364266T3 (da)
HU (1) HUP0101160A2 (da)
IL (1) IL138801A0 (da)
NO (1) NO20004946L (da)
PL (1) PL343322A1 (da)
PT (1) PT1069185E (da)
SK (1) SK14812000A3 (da)
TR (2) TR200101541T2 (da)
WO (1) WO1999051743A1 (da)

Families Citing this family (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0833911B1 (en) 1995-06-07 2004-05-12 Ortho Pharmaceutical Corporation Cdr-grafted anti-tissue factor antibodies and methods of use thereof
US6703197B1 (en) * 1996-11-27 2004-03-09 Martinex R&D, Inc. Human methionine synthase: cloning, and methods for evaluating risk of neural tube defects, cardiovascular disease, and cancer
US20030109680A1 (en) * 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US20060235209A9 (en) * 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US7749498B2 (en) * 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US7764130B2 (en) * 1999-01-22 2010-07-27 Multigig Inc. Electronic circuitry
IL148980A0 (en) * 1999-10-01 2002-11-10 Chugai Pharmaceutical Co Ltd An antibody to human tissue factor and experimental animals having inserted cells with the gene encoding human tissue factor
DE19962583A1 (de) * 1999-12-23 2001-06-28 Mueller Hermelink Hans Konrad Antikörper gegen Plasmazellen
AU5081401A (en) * 2000-03-16 2001-10-03 Genentech Inc Anti-tissue factor antibodies with enhanced anticoagulant potency
US6703494B2 (en) 2000-03-16 2004-03-09 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
US8632778B2 (en) 2000-08-11 2014-01-21 Chugai Seiyaku Kabushiki Kaisha Stabilized anti-interleukin-6 antibody-containing preparations
ES2869895T3 (es) 2001-03-09 2021-10-26 Chugai Pharmaceutical Co Ltd Método de purificación de proteínas
WO2002078738A1 (fr) * 2001-03-26 2002-10-10 Koji Suzuki Agents ameliorant la rheologie sanguine
ATE414537T1 (de) * 2001-08-29 2008-12-15 Chugai Pharmaceutical Co Ltd Antikörper enthaltende stabilisierte zubereitungen
CZ2004454A3 (cs) * 2001-10-02 2004-09-15 Novo Nordisk A/S Protilátky lidského tkáňového faktoru
US20030190705A1 (en) * 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules
AU2002362197A1 (en) 2001-12-28 2003-07-24 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing protein
CN100412090C (zh) * 2002-05-01 2008-08-20 舍林股份公司 作为抗凝剂的新的靶向组织因子的血栓调节蛋白融合蛋白
GB0210783D0 (en) * 2002-05-10 2002-06-19 Polonelli Luciano Anti-microbial polypeptides
JPWO2003099324A1 (ja) * 2002-05-23 2005-09-22 中外製薬株式会社 組織因子阻害剤中和剤及び活性型血液凝固第ｖｉｉ因子製剤中和剤
WO2004019966A1 (ja) 2002-08-27 2004-03-11 Chugai Seiyaku Kabushiki Kaisha タンパク質溶液製剤の安定化方法
CN100522989C (zh) 2002-09-11 2009-08-05 中外制药株式会社 纯化蛋白质的方法
WO2004039842A2 (en) * 2002-10-31 2004-05-13 Novo Nordisk A/S Humanized tissue factor antibodies
US7223393B2 (en) * 2003-02-07 2007-05-29 Pdl Biopharma, Inc Amphiregulin antibodies and their use to treat cancer and psoriasis
AU2004216298B2 (en) * 2003-02-28 2009-04-23 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
US7425328B2 (en) * 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
JP2006526641A (ja) * 2003-05-30 2006-11-24 セントカー・インコーポレーテツド 抗−組織因子抗体を用いる腫瘍成長を抑制する方法
CN1863556B (zh) * 2003-06-19 2012-05-16 吉宁特有限公司 用于治疗凝血相关紊乱的组合物和方法
EP1667718A4 (en) * 2003-08-29 2007-05-02 Centocor Inc METHOD FOR STIMULATING THE SURVIVAL OF A GRAFT WITH ANTI-TISSUE FACTOR ANTIBODY
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
AU2003271186A1 (en) 2003-10-14 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
HUE038955T2 (hu) * 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
WO2006037604A1 (en) 2004-10-01 2006-04-13 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel antibodies directed to the mammalian eag1 ion channel protein
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
BRPI0608468A2 (pt) * 2005-03-25 2010-01-05 Glycart Biotechnology Ag moléculas de ligação a antìgeno direcionadas a mcsp e tendo afinidade de ligação a receptor de fc e função efetora aumentadas
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
EP2824183B1 (en) 2005-04-08 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Methods for producing bispecific antibodies
EP1888649A2 (en) * 2005-05-09 2008-02-20 GlycArt Biotechnology AG Antigen binding molecules having modified fc regions and altered binding to fc receptors
CA2619725C (en) 2005-08-18 2016-06-07 Ramot At Tel Aviv University Ltd. Single chain antibodies against beta-amyloid peptide
AU2006290433B2 (en) 2005-08-26 2012-06-07 Roche Glycart Ag Modified antigen binding molecules with altered cell signaling activity
JP5231810B2 (ja) 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
EP4793360A2 (en) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
JP5144499B2 (ja) 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
US20090285819A1 (en) * 2006-11-15 2009-11-19 Functional Genetics, Inc. Methods and compositions for treating influenza
FR2909092B1 (fr) * 2006-11-24 2012-10-19 Pf Medicament Nouveaux anticorps anti-proliferation
PL2662091T3 (pl) 2006-12-01 2019-05-31 Novartis Ag Przeciwciała skierowane przeciwko selektynie P i sposoby ich zastosowania do leczenia chorób zapalnych
ES2687808T3 (es) 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
TWI548418B (zh) 2007-12-05 2016-09-11 中外製藥股份有限公司 Anti-NR10 / IL-31RA antibody and its use
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
MY155049A (en) * 2008-03-14 2015-08-28 Allergan Inc Immuno-based botolinum toxin serotype a activity assay
JP5639039B2 (ja) 2008-04-11 2014-12-10 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
WO2010002862A2 (en) * 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
PL2305300T3 (pl) 2008-07-10 2016-09-30 Kompozycja farmaceutyczna do leczenia i zapobiegania nowotworowi
DK2322221T3 (da) 2008-08-05 2014-09-01 Toray Industries Farmaceutisk sammensætning til behandling og forebyggelse af cancer
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
EP2380976A4 (en) 2008-12-25 2012-11-07 Univ Osaka HUMAN ANTIBODY AGAINST HUMAN FLUX VIRUS
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
TWI544077B (zh) 2009-03-19 2016-08-01 中外製藥股份有限公司 Antibody constant region change body
CN102459344A (zh) 2009-05-15 2012-05-16 中外制药株式会社 抗axl抗体
EP2436397B1 (en) 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
CN101717447B (zh) * 2009-12-17 2012-06-27 山西省生物研究所 一种抗人重组组织因子单克隆抗体的制备方法
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
KR101842893B1 (ko) 2010-02-04 2018-03-28 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
AU2011211699B2 (en) 2010-02-04 2015-01-22 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
KR101871704B1 (ko) 2010-02-04 2018-06-27 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
JP5845899B2 (ja) 2010-02-04 2016-01-20 東レ株式会社 癌の治療及び／又は予防用医薬組成物
BR112012018951C8 (pt) 2010-02-04 2020-06-23 Toray Industries anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
JP6055404B2 (ja) 2010-06-15 2016-12-27 ゲンマブ エー／エス 組織因子に対するヒト抗体薬物結合体
CN105859889B (zh) 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
JP6176849B2 (ja) 2011-07-19 2017-08-09 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
KR101968499B1 (ko) 2011-08-04 2019-04-12 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
ES2672695T3 (es) 2011-08-04 2018-06-15 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la profilaxis del cáncer
CN103764825B (zh) 2011-08-04 2015-09-02 东丽株式会社 癌的治疗和/或预防用药物组合物
CN103889555B (zh) 2011-09-01 2018-10-26 中外制药株式会社 通过超滤制备包含高度浓缩的抗体的组合物的方法
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
ES2739380T3 (es) 2012-02-21 2020-01-30 Toray Industries Composición farmacéutica para el tratamiento del cáncer
AU2013223143B2 (en) 2012-02-21 2017-12-21 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
MX357505B (es) 2012-02-21 2018-07-12 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
IN2014KN01714A (da) 2012-02-21 2015-10-23 Toray Industries
US9428581B2 (en) 2012-03-30 2016-08-30 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of gallbladder cancer
PT2832365T (pt) 2012-03-30 2018-01-24 Toray Industries Composição farmacêutica para o tratamento e/ou prevenção do cancro hepático
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
US9345766B2 (en) 2012-08-30 2016-05-24 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-ERBB3 agents
BR112015006634B1 (pt) 2012-09-28 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Método e kit para avaliação de reação de coagulação sanguínea
CA2918989C (en) 2013-08-09 2021-11-02 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
CA2925256C (en) 2013-09-27 2023-08-15 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
US10654933B2 (en) 2013-12-27 2020-05-19 Chugai Seiyaku Kabushiki Kaisha Method for purifying antibody having low isoelectric point
US10538591B2 (en) 2014-03-10 2020-01-21 The Brigham And Women's Hospital, Inc. Anti-fibulin-3 antibodies and uses thereof
TW201625299A (zh) 2014-06-20 2016-07-16 Chugai Pharmaceutical Co Ltd 用於因第ｖｉｉｉ凝血因子及／或活化的第ｖｉｉｉ凝血因子的活性降低或欠缺而發病及／或進展的疾病之預防及／或治療之醫藥組成物
EP3185004A4 (en) 2014-08-20 2018-05-30 Chugai Seiyaku Kabushiki Kaisha Method for measuring viscosity of protein solution
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
WO2016065329A1 (en) * 2014-10-24 2016-04-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
US10550187B2 (en) 2014-10-24 2020-02-04 Incept, Llc Extra luminal scaffold
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
EA201791366A1 (ru) 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся Антитела к c5 и способы их применения
CN114773469B (zh) 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
TWI759261B (zh) 2015-02-27 2022-04-01 日商中外製藥股份有限公司 Ｉｌ－６受體抗體用於製備醫藥組成物的用途
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
CA2978038A1 (en) 2015-04-17 2016-10-20 F. Hoffmann-La Roche Ag Combination therapy with coagulation factors and multispecific antibodies
CA3004830A1 (en) 2015-11-11 2017-05-18 Opi Vi- Ip Holdco Llc Composition and methods for anti-tnfr2 antibodies
US20200270363A1 (en) 2015-12-25 2020-08-27 Chugai Seiyaku Kabushiki Kaisha Antibody having enhanced activity, and method for modifying same
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
EP3431102A4 (en) 2016-03-14 2019-09-25 Chugai Seiyaku Kabushiki Kaisha CELL DAMAGING THERAPEUTIC MEDICAMENT FOR USE IN CANCER THERAPY
JP6939555B2 (ja) 2016-03-28 2021-09-22 東レ株式会社 癌の治療及び／又は予防用医薬組成物
AU2017255077B2 (en) 2016-04-28 2024-05-16 Chugai Seiyaku Kabushiki Kaisha Antibody-containing preparation
KR20230047507A (ko) 2016-06-27 2023-04-07 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 암 치료 조합
CN116271014A (zh) 2016-08-05 2023-06-23 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
US11352438B2 (en) 2016-09-06 2022-06-07 Chugai Seiyaku Kabushiki Kaisha Methods of using a bispecific antibody that recognizes coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X
WO2018079740A1 (ja) 2016-10-28 2018-05-03 東レ株式会社 癌の治療及び／又は予防用医薬組成物
JP7209298B2 (ja) 2017-03-31 2023-01-20 公立大学法人奈良県立医科大学 血液凝固第ｖｉｉｉ因子の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｉｘ因子異常症の予防および／または治療に用いられる医薬組成物
US20200109390A1 (en) 2017-04-27 2020-04-09 Chugai Seiyaku Kabushiki Kaisha Coagulation factor ix with improved pharmacokinetics
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
TW201922796A (zh) * 2017-10-30 2019-06-16 國立研究開發法人國立癌症研究中心 可用於實體腫瘤治療之抗體及其抗體－藥物共軛物以及含其之抗癌劑
KR20260090008A (ko) 2017-11-01 2026-06-16 추가이 세이야쿠 가부시키가이샤 생물 활성이 저하된 항체 배리언트 및 아이소폼
CN111727075B (zh) * 2017-11-27 2024-04-05 普渡制药公司 靶向人组织因子的人源化抗体
KR20240134250A (ko) * 2018-01-04 2024-09-06 아이코닉 테라퓨틱스, 인코포레이티드 항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
WO2019189780A1 (ja) 2018-03-30 2019-10-03 東レ株式会社 癌の治療及び／又は予防用医薬組成物
JP7460608B2 (ja) 2018-05-07 2024-04-02 ジェンマブ エー／エス 抗ｐｄ－１抗体と抗組織因子抗体－薬物コンジュゲートとの組み合わせを用いるがんの治療方法
JP7549530B2 (ja) 2018-05-21 2024-09-11 中外製薬株式会社 ガラス容器に封入された凍結乾燥製剤
EP3805112A4 (en) 2018-05-28 2022-03-09 Chugai Seiyaku Kabushiki Kaisha FILLING NOZZLE
US20210355199A1 (en) 2018-06-28 2021-11-18 University Of Virginia Patent Foundation Compositions and methods for detecting and regulating fibronectin-integrin interaction and signaling
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
US20220381790A1 (en) 2019-02-11 2022-12-01 University Of Virginia Patent Foundation Selection and blockade of fertilization competent male and female gametes
WO2020186247A1 (en) 2019-03-13 2020-09-17 University Of Virginia Patent Foundation Compositions and methods for promoting islet viability and enhancing insulin secretion
CA3133909A1 (en) 2019-04-18 2020-10-22 Elpida TSIKA Novel molecules for therapy and diagnosis
MX2022006676A (es) 2019-12-04 2022-07-05 Ac Immune Sa Nuevas moleculas para terapia y diagnostico.
CA3175129A1 (en) 2020-03-12 2021-09-19 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
JP7797875B2 (ja) 2020-03-12 2026-01-14 東レ株式会社 癌の治療及び／又は予防のための医薬品
JPWO2021182574A1 (da) 2020-03-12 2021-09-16
EP4119157A4 (en) 2020-03-12 2024-03-27 Toray Industries, Inc. MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
CA3175127A1 (en) 2020-03-12 2021-09-16 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
TW202144429A (zh) 2020-05-14 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ｃｄ２５抗體、其抗原結合片段及其醫藥用途
JP7752613B2 (ja) 2020-05-22 2025-10-10 中外製薬株式会社 凝固第ｖｉｉｉ因子（ｆ．ｖｉｉｉ）機能代替活性を有する物質を中和する抗体
WO2022079297A1 (en) 2020-10-16 2022-04-21 Ac Immune Sa Antibodies binding to alpha-synuclein for therapy and diagnosis
JP2024500115A (ja) 2020-12-18 2024-01-04 エイシー イミューン ソシエテ アノニム 抗体デリバリー
AU2022298240A1 (en) 2021-06-23 2024-01-18 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
EP4360648A4 (en) 2021-06-23 2025-10-08 Toray Industries MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
KR20240042415A (ko) 2021-07-27 2024-04-02 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
EP4378478A4 (en) 2021-07-27 2025-11-12 Toray Industries MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
AU2022319362A1 (en) 2021-07-27 2024-02-29 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CA3230737A1 (en) 2021-09-03 2023-03-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
EP4413998A4 (en) 2021-10-08 2026-02-25 Chugai Pharmaceutical Co Ltd METHOD FOR PREPARING A PRE-FILLED SYRINGE FORMULATION
KR20250005335A (ko) 2022-04-26 2025-01-09 추가이 세이야쿠 가부시키가이샤 의약 제제 함유 필터 내장 시린지
AU2023298568A1 (en) 2022-06-30 2025-01-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
AU2023329564A1 (en) 2022-08-24 2025-02-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CN119768181A (zh) 2022-08-24 2025-04-04 东丽株式会社 用于癌的治疗和/或预防的药品
JPWO2024043252A1 (da) 2022-08-24 2024-02-29
AU2023334696A1 (en) 2022-08-30 2025-02-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CN119789868A (zh) 2022-08-30 2025-04-08 东丽株式会社 用于癌的治疗和/或预防的药品
CN115975033A (zh) * 2022-10-10 2023-04-18 中国科学院微生物研究所 一种lilrb1单克隆抗体及其应用
KR20250118852A (ko) 2022-12-23 2025-08-06 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
WO2024177535A1 (ru) 2023-02-21 2024-08-29 Акционерное общество "ГЕНЕРИУМ" Фармацевтическая композиция и способ профилактики и лечения недостаточности лизосомального фермента у субъекта, имеющего мукополисахаридоз ii типа
EP4691490A1 (en) 2023-03-31 2026-02-11 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
WO2024214811A1 (ja) 2023-04-14 2024-10-17 中外製薬株式会社 タンパク質含有医薬製剤の安定化方法
JPWO2025058000A1 (da) 2023-09-13 2025-03-20
WO2025093720A1 (en) 2023-11-02 2025-05-08 Betasense Gmbh Methods for determining misfolded alpha-synuclein in a sample
CN119454938B (zh) * 2024-11-15 2025-07-25 广州骐骥生物科技有限公司 一种枸橼酸透析浓缩液及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5223427A (en) 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US5437864A (en) 1987-03-31 1995-08-01 The Scripps Research Institute Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
AU668349B2 (en) 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
AU5093593A (en) * 1992-08-28 1994-03-29 Scripps Research Institute, The Inhibition of tumor metastasis via neutralization of tissue factor function
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
EP0833911B1 (en) * 1995-06-07 2004-05-12 Ortho Pharmaceutical Corporation Cdr-grafted anti-tissue factor antibodies and methods of use thereof

Also Published As

Publication number Publication date
JP4180106B2 (ja) 2008-11-12
CN1303431A (zh) 2001-07-11
US7494647B2 (en) 2009-02-24
EP2363484A3 (en) 2012-04-25
NO20004946D0 (no) 2000-10-02
EP1069185B1 (en) 2011-06-08
US6677436B1 (en) 2004-01-13
US20040044187A1 (en) 2004-03-04
AU752730B2 (en) 2002-09-26
KR20010042435A (ko) 2001-05-25
HUP0101160A2 (hu) 2001-08-28
WO1999051743A1 (en) 1999-10-14
EP1069185A1 (en) 2001-01-17
IL138801A0 (en) 2001-10-31
AU3055699A (en) 1999-10-25
PT1069185E (pt) 2011-08-11
CA2325346A1 (en) 1999-10-14
EP2363484A2 (en) 2011-09-07
PL343322A1 (en) 2001-08-13
JP3998419B2 (ja) 2007-10-24
TR200101541T2 (tr) 2002-06-21
JP2008161198A (ja) 2008-07-17
EP1069185A4 (en) 2005-01-19
TR200002885T2 (tr) 2000-12-21
ATE512225T1 (de) 2011-06-15
BR9909382A (pt) 2000-12-05
SK14812000A3 (sk) 2001-08-06
DK1069185T3 (da) 2011-06-27
ES2364266T3 (es) 2011-08-30

Similar Documents

Publication Publication Date Title
DK1069185T3 (da) Humaniseret antistof mod human vævsfaktor (TF) og fremgangsmåde til at konstruere humaniseret antistof
AU2936395A (en) Reconstituted human antibody against human interleukin-8
ATE512224T1 (de) Rekonstituierter menschlicher anti-hm.1 antikörper
DK0671927T3 (da) Neutraliserende humane monoklonale antistoffer mod respiratorisk syncytialvirus
ATE180511T1 (de) Humanisierter b-b10, ein anti-il-2-rezeptor- antikörper
LU92912I2 (fr) Mépolizumab et ses dérivés pharmaceutiquement acceptables (nucala)
NO20063224L (no) Anti-MPL-antistoff
IL160358A0 (en) Human antibodies specific for interleukin 15 (il-15)
EP1126878A4 (en) HEPARANASE ACTIVITY TO NEUTRALIZE AN ANTI-HEPANARASE MONOCLONAL ANTIBODY
PT699237E (pt) Fvs de cadeia anti-egfr e anticorpos anti-egfr
AU2349697A (en) Monoclonal antibodies against the interferon receptor with neutralizing activity against type I interferon
FI973469A0 (fi) Menetelmä tekijän IX valmistamiseksi biologisista lähteistä

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application